Big news! Novartis’ Fingolimod Hydrochloride (trade name: Gilenya) will be marketed in China soon. As the world’s first oral drug for multiple sclerosis (MS), fingolimod achieved global sales of USD3.341 billion in 2018, making it a well-deserved “blockbuster drug”.
